| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-146-12-200706190-00159 |
| P698 | PubMed publication ID | 17470824 |
| P50 | author | Paul Rutgeerts | Q30247987 |
| Jean-Frédéric Colombel | Q30248037 | ||
| Geert D'Haens | Q37066728 | ||
| William Jeffery Sandborn | Q64364605 | ||
| Stephen B Hanauer | Q87669570 | ||
| Robert Enns | Q88367599 | ||
| Remo Panaccione | Q92078930 | ||
| P2093 | author name string | Ju Li | |
| Jeffrey D Kent | |||
| Paul F Pollack | |||
| Marie R Rosenfeld | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adalimumab | Q348260 |
| P304 | page(s) | 829-838 | |
| P577 | publication date | 2007-04-30 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial | |
| P478 | volume | 146 |
| Q37672058 | A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease |
| Q50526241 | A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. |
| Q50905492 | A Case Report of Acute Cellular Rejection Following Intestinal Transplantation Managed With Adalimumab |
| Q41482228 | A Health Survey of Gastroenterologist Prescribing Practices of Adalimumab for Treatment of Crohn's Disease: Final Results |
| Q82607225 | A Nationwide Analysis of Changes in Severity and Outcomes of Inflammatory Bowel Disease Hospitalizations |
| Q94354288 | A SPECIAL MEETING REVIEW EDITION: Highlights in Anti-Tumor Necrosis Factor Monitoring and Antibody Monitoring From the 2014 DDW Meeting: Digestive Disease Week 2014 May 3-6, 2014 • Chicago, Illinois: Special Reporting on:• Therapeutic Monitoring of |
| Q51041658 | A case of Crohn's disease that developed anti-infliximab and anti-adalimumab antibodies |
| Q35901531 | A mechanistic review on plant-derived natural compounds as dietary supplements for prevention of inflammatory bowel disease. |
| Q34353032 | A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases |
| Q48420954 | A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease |
| Q40006169 | A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease |
| Q26865009 | A review of the impact of biologics on surgical complications in Crohn's disease |
| Q38707864 | A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease |
| Q33514539 | A systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease |
| Q88249578 | ACG Clinical Guideline: Management of Crohn's Disease in Adults |
| Q43294482 | Acute bilateral phrenic neuropathy following treatment with adalimumab |
| Q53838959 | Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies. |
| Q33562796 | Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement |
| Q38005811 | Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients |
| Q43510384 | Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease |
| Q43515258 | Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study. |
| Q48484232 | Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease |
| Q37307855 | Adalimumab for the treatment of Crohn's disease |
| Q37209889 | Adalimumab for the treatment of fistulas in patients with Crohn's disease |
| Q46670774 | Adalimumab for the treatment of inflammatory bowel disease. |
| Q37290464 | Adalimumab in Crohn's disease |
| Q36215552 | Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients |
| Q38895960 | Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target |
| Q37816445 | Adalimumab in ulcerative colitis: hypes and hopes |
| Q62476197 | Adalimumab is effective in achieving clinical and endoscopic long-term deep remission: A case report |
| Q48172806 | Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. |
| Q30679247 | Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. |
| Q35213972 | Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis |
| Q37404893 | Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases |
| Q42653303 | Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease |
| Q26829488 | Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial |
| Q51743452 | Adalimumab treatment in children with refractory Crohn's disease. |
| Q39748377 | Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease |
| Q38098468 | Adalimumab: a review of its use in the treatment of patients with ulcerative colitis |
| Q24234197 | Adverse effects of biologics: a network meta-analysis and Cochrane overview |
| Q35645531 | Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis |
| Q37215524 | Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease |
| Q37582470 | An analysis of the placebo effect in Crohn's disease over time |
| Q37462968 | An evidence-based review of natalizumab therapy in the management of Crohn's disease. |
| Q37862584 | An evidence-based systematic review on medical therapies for inflammatory bowel disease |
| Q50110700 | An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients |
| Q45151393 | Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort |
| Q90672631 | Anti-TNF Therapy in Crohn's Disease |
| Q41913944 | Anti-TNF failures in Crohn's disease. |
| Q41440826 | Anti-TNF therapy for paediatric IBD: the Scottish national experience |
| Q37965581 | Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? |
| Q82710946 | Anti-TNF-alpha treatment strategies: results and clinical perspectives |
| Q38652276 | Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future |
| Q37823325 | Anti-adhesion molecule therapy for inflammatory bowel disease |
| Q39258568 | Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab. |
| Q35526652 | Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management |
| Q37676831 | Anti-tumour necrosis factor-alpha therapies in Crohn's disease |
| Q39019308 | Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial |
| Q50713607 | Approach to Optimize Anti-TNF-α Therapy in Patients With IBD. |
| Q26864906 | Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data |
| Q37856191 | Assessing response and loss of response to biological therapies in IBD. |
| Q53813065 | Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease. |
| Q24241604 | Bacille Calmette-Guerin (BCG) vaccine for induction of remission in Crohn's disease |
| Q37609746 | Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease |
| Q38630959 | Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. |
| Q33916292 | Biologic Therapies for Crohn's Disease: Update from the 2009 ACG Meeting |
| Q38568898 | Biologic agents for IBD: practical insights |
| Q38182208 | Biologic therapies in inflammatory bowel disease |
| Q38818458 | Biologic therapies in the treatment of sarcoidosis |
| Q40429147 | Biological drugs for inducing remission in patients with Crohn's disease: determining statistical equivalence according to evidence-based methods |
| Q37960183 | Biological therapies for inflammatory bowel disease: controversies and future options |
| Q38217223 | Biological therapies for spondyloarthritis |
| Q38254978 | Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses |
| Q31017419 | Biologics in inflammatory bowel disease: what are the data? |
| Q90339285 | British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults |
| Q91789183 | Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease |
| Q37223169 | Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease |
| Q81725630 | Certolizumab pegol |
| Q84936139 | Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis |
| Q46117793 | Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease |
| Q46247849 | Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? |
| Q52561556 | Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. |
| Q91677815 | Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus |
| Q36089928 | Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan |
| Q45862308 | Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease |
| Q37055162 | Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita |
| Q82849348 | Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease |
| Q45083749 | Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. |
| Q36551351 | Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease |
| Q52843096 | Commentary: infliximab or adalimumab in Crohn's disease? |
| Q39542719 | Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn's disease following ileocolonic resection |
| Q40722978 | Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease |
| Q38046743 | Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice |
| Q38118313 | Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response |
| Q38293796 | Conventional drug therapy for inflammatory bowel disease |
| Q36714704 | Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab |
| Q52581473 | Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist. |
| Q52670879 | Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. |
| Q58803120 | Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden |
| Q38824505 | Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe |
| Q40526989 | Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab |
| Q37169127 | Crohn's disease clinical issues and treatment: what the radiologist needs to know and what the gastroenterologist wants to know |
| Q37511803 | Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature |
| Q37011959 | Crohn's disease: a review of current treatment with a focus on biologics. |
| Q34593801 | Crohn's disease: beyond antagonists of tumour necrosis factor |
| Q34551302 | Current Research in Crohn's Disease and Ulcerative Colitis: Highlights from the 2010 ACG Meeting |
| Q39278646 | Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. |
| Q34883210 | Current and emerging drugs for the treatment of inflammatory bowel disease |
| Q41174352 | Current directions of biologic therapies in inflammatory bowel disease |
| Q34127277 | Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease |
| Q38068963 | Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update |
| Q30902172 | Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases |
| Q56968600 | Cyclophosphamide Pulse Therapy in Severe Refractory Crohn's Disease: A Retrospective Multicenter Case Series |
| Q37720748 | Decision-making in ileocecal Crohn's disease management: surgery versus pharmacotherapy |
| Q46373775 | Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease |
| Q51158618 | Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay |
| Q37372471 | Diagnosis and management of fistulizing Crohn's disease |
| Q40194284 | Dietary Therapy with the Crohn's Disease Exclusion Diet is a Successful Strategy for Induction of Remission in Children and Adults Failing Biological Therapy |
| Q49500732 | Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab |
| Q42675644 | Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics |
| Q37073426 | Drug safety in Crohn's disease therapy. |
| Q37324567 | Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. |
| Q43485861 | Editorial: improved efficacy of biological maintenance therapy in "early" compared with "late" Crohn's disease: strike while the iron is hot with anti-TNF agents? |
| Q34303155 | Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first "real-life" experience in primary gastroenterology centers in Italy |
| Q36310429 | Effectiveness of infliximab after adalimumab failure in Crohn's disease |
| Q42151036 | Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy |
| Q40234039 | Efficacy and Factors Associated with Treatment Response of Intravenous Immunoglobulin in Inpatients with Refractory Inflammatory Bowel Diseases |
| Q64285334 | Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies |
| Q51853406 | Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). |
| Q35177220 | Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials |
| Q37345854 | Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults |
| Q35268107 | Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial |
| Q98177931 | Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial |
| Q34408865 | Efficacy and safety of adalimumab in Crohn's disease |
| Q37880288 | Efficacy and safety of adalimumab in Crohn's disease: meta-analysis of placebo-controlled trials |
| Q38425123 | Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice |
| Q38702997 | Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis |
| Q36658432 | Efficacy of Adalimumab in Korean Patients with Crohn's Disease |
| Q36557868 | Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort |
| Q53191257 | Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. |
| Q53838483 | Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. |
| Q37853359 | Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis |
| Q34507117 | Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study |
| Q38379118 | Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study |
| Q46378234 | Elective switching from infliximab to adalimumab in stable Crohn's disease |
| Q42281646 | Elevated risk of opportunistic viral infection in patients with Crohn's disease during biological therapies: a meta analysis of randomized controlled trials |
| Q36039436 | Emerging drugs for the treatment of ulcerative colitis |
| Q26829392 | Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan |
| Q50079201 | Evidence-based clinical practice guidelines for inflammatory bowel disease. |
| Q89859893 | Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn's disease: the Indian experience |
| Q88923906 | Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease |
| Q37892879 | Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease |
| Q38232919 | Factors affecting response to biologic treatment in psoriasis. |
| Q38086355 | First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? |
| Q35559305 | From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease |
| Q40594199 | Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease |
| Q38370406 | Guidelines for medical treatment of Crohn's perianal fistulas: critical evaluation of therapeutic trials |
| Q37539703 | Hepatosplenic T-cell lymphoma in a patient with Crohn's disease |
| Q34178540 | Highlights from digestive disease week 2010. |
| Q37578507 | How to manage difficult Crohn's disease: optimum delivery of anti-TNFs |
| Q39032463 | IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy |
| Q57239820 | Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy |
| Q37660661 | Immunosuppressive therapies for inflammatory bowel disease |
| Q41857036 | Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model |
| Q38810448 | Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases |
| Q37719806 | Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease |
| Q37367325 | Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies |
| Q42375893 | Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial |
| Q47961270 | Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches |
| Q52727908 | Inflammatory Cytokine Profile in Crohn's Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy. |
| Q84593979 | Inflammatory bowel disease in the elderly |
| Q27005445 | Inflammatory pathways of importance for management of inflammatory bowel disease |
| Q40074660 | Infliximab in Crohn's disease: early and long-term treatment |
| Q35304737 | Infliximab to treat Crohn's disease: an update. |
| Q38943959 | Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases |
| Q35562290 | Introducing vedolizumab to clinical practice: who, when, and how? |
| Q38217832 | Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? |
| Q55505680 | Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease? |
| Q26766368 | Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example |
| Q33362566 | Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). |
| Q28072729 | Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear? |
| Q47932426 | Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea |
| Q51872306 | Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. |
| Q42662898 | Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease |
| Q38425063 | Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study |
| Q48265479 | Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. |
| Q37853354 | Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review |
| Q37378998 | Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. |
| Q36439889 | Management and evaluation of extra-articular manifestations in spondyloarthritis |
| Q33819478 | Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease |
| Q37708656 | Management of Crohn's disease in poor responders to adalimumab |
| Q35773115 | Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease |
| Q38102982 | Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab |
| Q38254573 | Management of inflammatory bowel disease in poor responders to infliximab |
| Q37822776 | Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies |
| Q37930978 | Management of psoriatic arthritis from the view of the dermatologist |
| Q35460367 | Managing refractory Crohn's disease: challenges and solutions |
| Q38116746 | Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for Crohn's disease |
| Q90320869 | Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More |
| Q26777722 | Medical Therapy of Perianal Crohn's Disease |
| Q55103450 | Medical and surgical management of perianal Crohn's disease. |
| Q34046139 | Medical management of Crohn's disease. |
| Q35505999 | Medical management of inflammatory bowel disease among Canadian gastroenterologists |
| Q37986622 | Medical therapy for pediatric inflammatory bowel disease |
| Q37111979 | Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. |
| Q33404394 | Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease |
| Q38823581 | MicroRNAs: how many in inflammatory bowel disease? |
| Q38011773 | Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease |
| Q36724093 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q34048010 | Multidisciplinary and evidence-based management of fistulizing perianal Crohn's disease |
| Q41060001 | NICE guidance for anti-tumour necrosis factor therapy in Crohn's disease: what does it mean for the inflammatory bowel disease community? |
| Q90289832 | Network meta-regression for ordinal outcomes: Applications in comparing Crohn's disease treatments |
| Q88140463 | Neuro-ophthalmic sarcoidosis |
| Q33612263 | New Data on the Use of Biologic Agents for Crohn's Disease and Ulcerative Colitis: Highlights from the 2009 CCFA Advances in IBD Meeting |
| Q38185687 | New biologic therapeutics for ulcerative colitis and Crohn's disease |
| Q38253844 | Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease |
| Q96952233 | Novel candidate drugs in anti-tumor necrosis factor refractory Crohn's diseases: in silico study for drug repositioning |
| Q35134059 | Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease |
| Q38104612 | Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials |
| Q37823322 | Optimal use of biologics in the management of Crohn's disease |
| Q26866940 | Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease |
| Q38822920 | Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. |
| Q37630743 | Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease). |
| Q38608158 | Optimizing biological therapy in Crohn's disease |
| Q37123773 | Optimizing drug therapy in inflammatory bowel disease. |
| Q37682873 | Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach. |
| Q37324635 | Optimizing treatment of inflammatory bowel diseases with biologic agents |
| Q43185875 | Orally administered extract from Prunella vulgaris attenuates spontaneous colitis in mdr1a(-/-) mice |
| Q39338382 | Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up |
| Q53331247 | Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. |
| Q37547257 | Overview of biologic therapy for Crohn's disease |
| Q37519645 | Overview of stem cell therapy for Crohn's disease. |
| Q96585237 | Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study |
| Q26796432 | Patient considerations in the management of ulcerative colitis - role of vedolizumab |
| Q37729206 | Patient outcomes after anti TNF-alpha drugs for Crohn's disease |
| Q36144557 | Patient perspectives on the impact of Crohn's disease: results from group interviews |
| Q41219043 | Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability |
| Q38369056 | Perianal Crohn's disease: a review |
| Q42722418 | Perianal Crohn's disease: is there something new? |
| Q57301026 | Perianal Fistulas in Patients With Crohn's Disease, Part 1: Current Medical Management |
| Q50200774 | Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy |
| Q26796415 | Pharmacologic therapy for inflammatory bowel disease refractory to steroids |
| Q26777084 | Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies |
| Q46103014 | Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study |
| Q57167308 | Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases |
| Q38200554 | Positioning therapy for Crohn's disease |
| Q46989239 | Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease |
| Q87866284 | Postoperative adalimumab maintenance therapy for Japanese patients with Crohn's disease: a single-center, single-arm phase II trial (CCOG-1107 study) |
| Q48102910 | Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations |
| Q34389885 | Practical medical management of Crohn's disease. |
| Q92002860 | Predicting Response to Vedolizumab in Inflammatory Bowel Disease |
| Q50764332 | Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. |
| Q49691610 | Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis |
| Q34699653 | Progress in the diagnosis and treatment of inflammatory bowel disease. |
| Q30242073 | Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD? |
| Q37679873 | Recent advances in the management of inflammatory bowel disease. |
| Q27027630 | Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease |
| Q57128202 | Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease |
| Q57265384 | Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects |
| Q90268996 | Resolution of Crohn's disease |
| Q37590676 | Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease |
| Q37871625 | Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy |
| Q38121115 | Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. |
| Q26999705 | Review article: anti-adhesion therapies for inflammatory bowel disease |
| Q37841686 | Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience |
| Q37810313 | Review article: medical, surgical and radiological management of perianal Crohn’s fistulas |
| Q37842605 | Review article: remission rates achievable by current therapies for inflammatory bowel disease |
| Q37869193 | Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. |
| Q34625984 | Review of the safety and efficacy of ustekinumab |
| Q28538974 | Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease |
| Q43988900 | Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse |
| Q38268598 | Safety considerations when using anti-TNFα therapy to treat Crohn's disease |
| Q38269243 | Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy |
| Q37662498 | Second Korean guidelines for the management of Crohn's disease |
| Q34275637 | Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial |
| Q37503367 | Selecting appropriate anti-TNF agents in inflammatory bowel disease |
| Q26750456 | Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab |
| Q42616840 | Sequential Combination Therapy Versus Monotherapy: A Lack of Benefit in Time to Inflammatory Bowel Disease-Related Surgery |
| Q38053455 | Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis |
| Q51069789 | Serum adalimumab concentration and clinical remission in patients with Crohn's disease |
| Q28266806 | Severe and steroid-resistant Crohn's disease |
| Q44640499 | Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease |
| Q47911969 | Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohn's Disease |
| Q47138621 | Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. |
| Q37204429 | Similar outcomes for anti-tumor necrosis factor-α antibody and immunosuppressant following seton drainage in patients with Crohn's disease-related anal fistula |
| Q37345918 | Specific considerations in the treatment of pediatric inflammatory bowel disease |
| Q39442118 | Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn's Disease. |
| Q64901646 | Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients. |
| Q55506747 | Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα). |
| Q38180195 | Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. |
| Q39121473 | Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. |
| Q38344622 | Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. |
| Q38205873 | Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease |
| Q37996426 | Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease |
| Q64070276 | Systematic review: outcomes and adverse events from randomised trials in Crohn's disease |
| Q38619950 | Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. |
| Q37579956 | Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. |
| Q28070271 | THERAPIES FOR CROHN'S DISEASE: a clinical update |
| Q38176154 | Tailoring anti-TNF therapy in IBD: drug levels and disease activity |
| Q38160905 | Targeting TNF-α for the treatment of inflammatory bowel disease |
| Q24241766 | Thalidomide and thalidomide analogues for induction of remission in Crohn's disease |
| Q99240847 | The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta |
| Q53061383 | The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy |
| Q62476205 | The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases |
| Q34147687 | The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? |
| Q42000636 | The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience |
| Q35634736 | The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA. |
| Q41451555 | The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. |
| Q35072606 | The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model |
| Q39037681 | The biologics of ulcerative colitis |
| Q57265386 | The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâ s disease after failure of two other anti-TNF antibodies |
| Q38182645 | The expanding role of therapeutic antibodies |
| Q37998606 | The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy |
| Q44803722 | The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies |
| Q38128946 | The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. |
| Q37301134 | The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents |
| Q34152778 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations |
| Q89450520 | The state of the art on treatment of Crohn's disease |
| Q47880080 | The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders |
| Q39834984 | Therapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach |
| Q90246589 | Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response |
| Q38180807 | Therapeutic peptides in inflammatory bowel disease |
| Q37965606 | Therapy for sarcoidosis: evidence-based recommendations |
| Q49109368 | Top-down Versus Step-up Prescribing Strategies for Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Inflammatory Bowel Disease |
| Q37778588 | Toxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune Diseases |
| Q50923712 | Treatment of Crohn's disease with certolizumab pegol |
| Q42708758 | Treatment of Crohn's-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I-IIa Clinical Trial. |
| Q38285619 | Treatment of IBD: where we are and where we are going |
| Q34477003 | Treatment of Sarcoidosis |
| Q30251864 | Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment |
| Q42269880 | Tumor Necrosis Factor-alpha Antibodies in Fistulizing Crohn's Disease: An Updated Systematic Review and Meta-analysis |
| Q38258440 | Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us? |
| Q24242101 | Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease |
| Q35052356 | Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis |
| Q33711741 | Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model? |
| Q35186975 | Update on the management of inflammatory bowel disease: specific role of adalimumab. |
| Q37905652 | Update on the management of ulcerative colitis |
| Q38337716 | Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it? |
| Q37829470 | Use of biological molecules in the treatment of inflammatory bowel disease. |
| Q27030762 | Use of the tumor necrosis factor-blockers for Crohn's disease |
| Q47203436 | Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| Q30390909 | Ustekinumab for the treatment of Crohn's disease |
| Q26771890 | Ustekinumab for the treatment of Crohn's disease: can it find its niche? |
| Q92300916 | Ustekinumab is effective in biological refractory Crohn's disease patients-regardless of approval study selection criteria |
| Q39120032 | Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy |
| Q38915294 | Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| Q26786018 | Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease |
| Q38102750 | Vercirnon for the treatment of Crohn's disease |
| Q37720746 | What is the optimal therapy for Crohn's disease: step-up or top-down? |
| Q81535940 | [Anti-TNF biologics in the treatment of chronic inflammatory bowel disease] |
| Q83250211 | [Recommendations for patients with Crohn's disease starting treatment with adalimumab: a rapid guide] |
| Q90007067 | [Therapeutic regimens using monoclonal antibodies in gastroenterology] |
Search more.